Filtered By:
Cancer: Colorectal Cancer

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 470 results found since Jan 2013.

On prioritising global health ' s triple crisis of sepsis, COVID-19 and antimicrobial resistance: a mixed-methods study from Malawi
Conclusion Our analysis revealed strong relationships between in-hospital mortality and hospital case volume in hospitals treating a small number of cases. The nonlinearity and nonm onotonicity of the estimated relationships indicate that studies applying conventional statistical approaches like logistic regression should consider these relationships adequately.
Source: Current Awareness Service for Health (CASH) - December 14, 2022 Category: Consumer Health News Source Type: news

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Incident Cardiovascular Diseases Among Survivors of High-Risk Stage II-III Colorectal Cancer: A Cluster-Wide Cohort Study
CONCLUSIONS: Exposure to adjuvant fluoropyrimidine-based chemotherapy was associated with an increased risk of CVD among survivors of high-risk stage II-III CRC. Cardiovascular risk monitoring of this group throughout cancer survivorship is advisable.PMID:36240841 | DOI:10.6004/jnccn.2022.7042
Source: Journal of the National Comprehensive Cancer Network : JNCCN - October 14, 2022 Category: Cancer & Oncology Authors: Shing Fung Lee Pui Lam Yip Balamurugan A Vellayappan Cheng Ean Chee Lea Choung Wong Eric Yuk-Fai Wan Esther Wai-Yin Chan Chak-Fei Lee Francis Ann-Shing Lee Miguel Angel Luque-Fernandez Source Type: research